Morgan Stanley Issues Positive Forecast for Neurocrine Biosciences (NASDAQ:NBIX) Stock Price

Key Points

• Morgan Stanley raised its Neurocrine Biosciences price target from $183 to $185 while maintaining an “equal weight” rating, implying roughly 10.7% upside. Analysts overall rate NBIX “Moderate Buy,” with an average target of $201.55.
• Neurocrine reported strong quarterly results, earning $3.29 per share versus the $1.91 consensus estimate and generating $1.12 billion in revenue, up 41.3% year over year.
• Shares rose 15% to $167.09, supported by strong demand for INGREZZA and raised 2026 sales guidance of $2.9 billion to $2.925 billion.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) had its price target upped by investment analysts at Morgan Stanley from $183.00 to $185.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The firm presently has an "equal weight" rating on the stock. Morgan Stanley's price target would indicate a potential upside of 10.72% from the company's current price.

Several other analysts have also recently issued reports on NBIX. UBS Group decreased their price objective on Neurocrine Biosciences from $231.00 to $214.00 and set a "buy" rating on the stock in a report on Tuesday, September 29th. Wedbush boosted their price target on shares of Neurocrine Biosciences from $185.00 to $194.00 and gave the stock an "outperform" rating in a research report on Monday, August 3rd. Mizuho raised shares of Neurocrine Biosciences to a "hold" rating in a research note on Wednesday, September 16th. Weiss Ratings upgraded shares of Neurocrine Biosciences from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Wednesday, October 14th. Finally, Piper Sandler lifted their price objective on shares of Neurocrine Biosciences from $210.00 to $215.00 and gave the stock an "overweight" rating in a research note on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, Neurocrine Biosciences presently has an average rating of "Moderate Buy" and an average target price of $201.55.

Neurocrine Biosciences Trading Up 15.0%

NBIX traded up $21.74 during trading on Tuesday, hitting $167.09. 2,074,404 shares of the company traded hands, compared to its average volume of 1,224,783. The company has a market cap of $16.98 billion, a PE ratio of 24.46, a P/E/G ratio of 0.64 and a beta of 0.36. Neurocrine Biosciences has a 1 year low of $122.14 and a 1 year high of $186.12. The stock's 50-day simple moving average is $146.49 and its two-hundred day simple moving average is $147.45.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last released its quarterly earnings data on Monday, November 2nd. The company reported $3.29 EPS for the quarter, beating the consensus estimate of $1.91 by $1.38. The business had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.04 billion. Neurocrine Biosciences had a net margin of 20.91% and a return on equity of 22.43%. The business's revenue was up 41.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.04 EPS. Equities analysts expect that Neurocrine Biosciences will post 7.72 EPS for the current year.

Insider Activity at Neurocrine Biosciences

In other Neurocrine Biosciences news, insider David Boyer sold 826 shares of Neurocrine Biosciences stock in a transaction on Monday, September 14th. The stock was sold at an average price of $157.45, for a total transaction of $130,053.70. Following the completion of the sale, the insider directly owned 8,722 shares of the company's stock, valued at $1,373,278.90. The trade was a 8.65% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Matt Abernethy sold 2,311 shares of Neurocrine Biosciences stock in a transaction dated Monday, September 14th. The shares were sold at an average price of $157.20, for a total value of $363,289.20. Following the completion of the sale, the chief financial officer owned 42,808 shares of the company's stock, valued at $6,729,417.60. The trade was a 5.12% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 4.60% of the company's stock.

Institutional Trading of Neurocrine Biosciences

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Raleigh Capital Management Inc. lifted its holdings in shares of Neurocrine Biosciences by 561.8% in the 3rd quarter. Raleigh Capital Management Inc. now owns 225 shares of the company's stock worth $32,000 after purchasing an additional 191 shares during the last quarter. Basecamp Wealth Advisors LLC increased its stake in Neurocrine Biosciences by 582.9% during the 1st quarter. Basecamp Wealth Advisors LLC now owns 239 shares of the company's stock valued at $31,000 after buying an additional 204 shares during the period. Cassaday & Co Wealth Management LLC bought a new stake in Neurocrine Biosciences during the first quarter worth approximately $33,000. TrinityBridge Ltd bought a new stake in shares of Neurocrine Biosciences in the 2nd quarter worth $45,000. Finally, Transamerica Financial Advisors LLC acquired a new stake in Neurocrine Biosciences in the 2nd quarter valued at about $48,000. Hedge funds and other institutional investors own 92.59% of the company's stock.

Key Stories Impacting Neurocrine Biosciences

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Strong Q3 results: Neurocrine reported adjusted earnings of $3.29 per share, well above analyst estimates ranging from $1.91 to $2.67 and up from $2.04 a year earlier. Revenue rose 41.3% year over year to approximately $1.12 billion, also exceeding expectations. Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results
• Positive Sentiment: INGREZZA outlook raised: Management increased 2026 net sales guidance for INGREZZA (valbenazine) to $2.9 billion-$2.925 billion. The company also surpassed $1 billion in quarterly net product sales for the first time, signaling strong demand across its portfolio. Neurocrine Biosciences Crosses $1 Billion in Quarterly Product Sales
• Positive Sentiment: Analyst targets increased: Piper Sandler raised its target from $210 to $215 and maintained an “overweight” rating. Canaccord Genuity lifted its target from $210 to $220 with a “buy” rating, while Royal Bank of Canada increased its target from $187 to $190 and reiterated “outperform.” The revisions indicate analysts see additional upside following the earnings beat.
• Neutral Sentiment: Investor focus remains on execution: Earnings-call coverage highlights the company’s continued commercial momentum and diversified medicines portfolio. Investors will likely monitor whether demand remains strong enough to support the raised guidance and sustain recent earnings growth. Neurocrine Q3 2026 Earnings Call Transcript

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is a San Diego-based biopharmaceutical company focused on discovering, developing and commercializing medicines for neurological, neuroendocrine and psychiatric disorders. The company's research programs target conditions in which treatments may address significant unmet medical needs.

Neurocrine's leading product is INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor approved in the United States for the treatment of tardive dyskinesia and chorea associated with Huntington's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.